
    
      This is a multicenter, randomized, open label, phase III study assessing the efficacy and
      safety of Almonertinib combined with or without chemotherapy as an adjuvant treatment in
      patients with epidermal growth factor receptor (EGFR) mutation positive stage II-IIIA
      non-squamous NSCLC following complete tumour resection: Eligible patients will be randomized
      to receive either Almonertinib alone (110mg, po, once daily) or Almonertinib (110mg, po, once
      daily) plus pemetrexed (500mg/m2, iv) and cisplatin (500mg/m2, iv) or pemetrexed (500mg/m2,
      iv) plus cisplatin (500mg/m2, iv) in a 3:2:1 ratio.
    
  